Skip to main content
Top

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

Published in:

Abstract

The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.
Title
Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis
Authors
Ryo Izumi
Toru Hashimoto
Hiroshi Kisanuki
Kei Ikuta
Wataru Otsuru
Soshun Asakawa
Shoei Yamamoto
Kayo Misumi
Takeo Fujino
Keisuke Shinohara
Shouji Matsushima
Kazuya Hosokawa
Shunsuke Katsuki
Taro Mori
Mikiko Hashisako
Yuki Tateishi
Takeshi Iwasaki
Yoshinao Oda
Shintaro Kinugawa
Kohtaro Abe
Publication date
21-11-2024
This content is only visible if you are logged in and have the appropriate permissions.

2025 ESMO Congress hub

Unlock your free and exclusive access to expert interviews, news, and more from the annual congress of the European Society for Medical Oncology.

Read more

Keynote webinar | Spotlight on progress in colorectal cancer

  • Live
  • Webinar | 11-12-2025 | 18:00 (CET)

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)

Prof. Antoni Castells
Prof. Edward Giovannucci
Developed by: Springer Medicine
Join the webinar
Webinar
SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

Join Professor Joy Ho as she leads a panel of Asia-Pacific-based experts, discussing real-life patient cases and their experiences with CAR T-cell therapy for the treatment of R/R DLBCL or R/R FL. Learn about how to identify appropriate patients for CAR T-cell therapy and how to optimize outcomes with this treatment modality. Gain insights into essential aspects of pre- and post-infusion management, as well as important considerations for treatment sequencing.

This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.

Sponsored by:
  • Novartis Pharma AG
Prof. Joy Ho
Prof. William Hwang
Dr. Kentaro Fukushima
Prof. Dok Hyun Yoon
Prof. Miki Ando
Developed by: Springer Health+
Learn more
Image Credits
ECG of patients with ICI-related fulminant myocarditis/© 2024, Ryo Izumi et al, Cardio-Oncology, Cancer cell screening and treatment concept/© artacet / iStock / Getty Images Plus, Colon cancer illustration/© (M) KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images, CAR T-cell attacking cancer cells/© LoveLive/stock.adobe.com